Jubilant Ingrevia Limited, a global integrated Life Science products and Innovative Solutions provider serving pharmaceutical, nutrition, agrochemical, consumer and industrial customers, Q2 FY25 revenue has reached Rs. 1,045 crore, a growth of 2.5% over corresponding quarter in last fiscal.

Profit after tax (PAT) reached Rs. 59 crore in Q2 FY25, a growth of 2.6% over corresponding quarter in last fiscal.   

Commenting on Q2 FY25 result, Shyam S. Bhartia, Chairman & Hari S. Bhartia, Co-Chairman said, “We are pleased to announce a healthy QoQ & YoY growth for the quarter, fueled by the enhanced performance of our Speciality Chemicals and Nutrition & Health Solutions Businesses, as well as the advantages gained from cost-saving measures implemented over the last few quarters."

"In the Speciality Chemicals Business, we saw a notable increase in volumes of high-margin Fine Chemicals business in both QoQ and YoY. The Pyridine & Picolines segment showed material YoY growth driven by higher volumes. The CDMO business continues to show good traction with customers across pharma, agrochemicals and semi-conductor segments (early stage)," commented Shyam S. Bhartia and Hari S. Bhartia.

"In the Nutrition and Health Solutions Business, significant YoY and QoQ growth was driven by increased volumes and prices of Niacinamide. Margin growth was boosted by better product mix with higher share of volumes (versus last quarter) from human grade products. In the Chemical Intermediates Business, QoQ growth was attributed to an increase in volumes of Ethyl Acetate and Acetic Anhydride. However, the YoY performance declined mainly due to lower prices," says Shyam S. Bhartia and Hari S. Bhartia.

"We expect to see improvements in our overall business performance in FY25, particularly within Speciality Chemicals and Nutrition & Health Solutions segments. Consistent with the last few quarters, our primary focus remains on customer-centricity, utilising the newly commissioned plants, enhancing operational efficiency leading to further improvement in margins. We expect sequential improvement in performance in Q3 and Q4, with H2 FY25 to be even better versus H1 FY25. We are committed to our growth plans through our ambitious Pinnacle 345 vision of achieving three times revenue and four times EBITDA within five years," added Shyam S. Bhartia and Hari S. Bhartia.